DVS Sciences, Inc. manufactures and has global distribution of novel bioanalytical solutions for use in biomarker discovery, biological research and possible clinical applications. The patented multi-parameter solution comprises a high-throughput mass cytometer for quantitative individual cell analysis, CyTOFÂ®, and a suite of MAXPARÂ® reagents, which include stable-isotope-tagged antibodies. The CyTOF â€“ MAXPAR system overcomes the limitations of conventional flow cytometry, simplifies sample preparation and simultaneously identifies up to 100 biomarkers with high resolution and wide dynamic range. CyTOF systems are installed in leading laboratories across the U.S., Canada and Asia.
Funding Rounds (1) - $14.6MUpdate
Current Team (9)Update
|May 17, 2016||PRNewswire UK All - Purigen Biosystems Receives $18.2M in Series A Financing led by 5AM Ventures and Roche Venture Fund|
|May 13, 2016||PRNewswire UK All - Global Flow Cytometry Market 2016-2018 - Two Major Companies Dominate the Market - Research and Markets|
|Feb 3, 2016||PE HUB - Pear Therapeutics scores $20 mln|
|Mar 19, 2015||PRWeb Sitemap - Pear Therapeutics Closes Financing|
|Jan 30, 2014||StrictlyVC - StrictlyVC: January 30, 2014|
|Jan 29, 2014||fiercediagnostics.com - Fluidigm and DVS Sciences Announce Agreement for Fluidigm to Acquire DVS Sciences – Creating a Single-Cell Technology Powerhouse|
|Jan 29, 2014||Xconomy - Fluidigm Acquires DVS Sciences for $207,500,000|
|May 2, 2012||Xconomy - The Affymetrix Alumni: Where Are They Now?|
639 N. Pastoria Ave.
Sunnyvale, CA 94085